Oncogenic KRAS Drives Immune Suppression in Colorectal Cancer

Kay Hänggi; Brian Ruffell

doi:10.1016/j.ccell.2019.03.008

Oncogenic KRAS Drives Immune Suppression in Colorectal Cancer

Cancer Cell. 2019 Apr 15;35(4):535-537. doi: 10.1016/j.ccell.2019.03.008.

Authors

Kay Hänggi¹, Brian Ruffell²

Affiliations

¹ Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA.
² Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA; Department of Breast Oncology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA. Electronic address: [email protected].

PMID: 30991021
DOI: 10.1016/j.ccell.2019.03.008

Abstract

In this issue of Cancer Cell, Liao et al. demonstrate that oncogenic KRAS drives an immune suppressive program in colorectal cancer by repressing IRF2 expression, which leads to downregulation of interferon responsive genes, enhanced expression of CXCL3 and recruitment of suppressive myeloid cells, and subsequent resistance to immune checkpoint blockade.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Colonic Neoplasms*
Colorectal Neoplasms / genetics*
Genes, ras
Humans
Interferon Regulatory Factor-2
Oncogenes
Proto-Oncogene Proteins p21(ras)

Substances

IRF2 protein, human
Interferon Regulatory Factor-2
KRAS protein, human
Proto-Oncogene Proteins p21(ras)